A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease

James W Smithy1, Paul B Chapman

  • 1From the Department of Medicine, Memorial Sloan Kettering Cancer Center.

PubMed

Insights

Immune checkpoint inhibitors and MAP kinase pathway inhibitors are revolutionizing melanoma treatment. This review covers their first-line use, highlighting future research directions for better patient outcomes.

Area of Science:

  • Oncology
  • Dermatology
  • Immunology

Background:

  • Significant advancements in melanoma treatment have emerged with immune checkpoint inhibitors and MAP kinase pathway inhibitors.
  • These therapies have transformed the management of advanced and metastatic melanoma.

Approach:

  • A comprehensive review of the clinical literature on first-line therapies for melanoma.
  • Incorporation of current practice patterns from leading melanoma groups.

Key Points:

  • First-line treatment strategies for melanoma are evolving rapidly.
  • Immune checkpoint inhibitors and MAP kinase inhibitors represent key therapeutic classes.
  • Areas of clinical uncertainty offer avenues for future research and improved patient outcomes.

Conclusions:

  • The first-line setting for melanoma management is increasingly defined by targeted therapies.
  • Further clinical investigation is crucial to optimize treatment strategies and enhance patient survival.
  • Understanding practice patterns alongside literature review provides a holistic view of current melanoma care.